<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=5.0, shrink-to-fit=no"/><link href="https://insights.covermymeds.com/css/covermystyles.css" rel="stylesheet"/><title>Specialty Medications: Hope for Patients, Hurdle for Healthcare | CoverMyMeds</title><meta name="description" content="In part three of our history of healthcare IT (HIT) series, we explore the origins and industry response to specialty medications"/><meta property="og:url" content="https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-medications-hope-for-patients-hurdle-for-healthcare"/><meta property="og:type" content="article"/><meta property="og:title" content="Specialty Medications: Hope for Patients, Hurdle for Healthcare"/><meta property="og:description" content="In part three of our history of healthcare IT (HIT) series, we explore the origins and industry response to specialty medications"/><meta property="og:image" content="https://images.ctfassets.net/70w6ftfzv4je/1X7Qqt4nSLPN5gx6GTtIeq/94bba734d2ce5194ce571d20649bdada/CMM_119300_HealthcareIT_Pt3_hero.jpeg"/><meta name="twitter:title" content="Specialty Medications: Hope for Patients, Hurdle for Healthcare"/><meta name="twitter:description" content="In part three of our history of healthcare IT (HIT) series, we explore the origins and industry response to specialty medications"/><meta name="twitter:image" content="https://images.ctfassets.net/70w6ftfzv4je/1X7Qqt4nSLPN5gx6GTtIeq/94bba734d2ce5194ce571d20649bdada/CMM_119300_HealthcareIT_Pt3_hero.jpeg"/><meta name="next-head-count" content="13"/><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><link rel="apple-touch-icon" sizes="152x152" href="https://insights.covermymeds.com/apple-touch-icon.png"/><link rel="icon" type="image/png" sizes="32x32" href="https://insights.covermymeds.com/favicon-32x32.png"/><link rel="icon" type="image/png" sizes="16x16" href="https://insights.covermymeds.com/favicon-16x16.png"/><link rel="manifest" href="https://insights.covermymeds.com/site.webmanifest"/><link rel="mask-icon" href="https://insights.covermymeds.com/safari-pinned-tab.svg" color="#5bbad5"/><meta name="msapplication-TileColor" content="#ffffff"/><meta name="theme-color" content="#ffffff"/><meta property="og:type" content="website"/><meta property="og:site_name" content="CoverMyMeds Insights"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:site" content="@CoverMyMeds"/><meta name="twitter:creator" content="@CoverMyMeds"/><script data-nscript="beforeInteractive">window.dataLayer = window.dataLayer || [];</script><script data-nscript="beforeInteractive">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-N7XK4K7V');</script><script data-nscript="beforeInteractive">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-WDWQ49P');</script><noscript data-n-css=""></noscript><script defer="" nomodule="" src="https://insights.covermymeds.com/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="https://www.googletagmanager.com/gtag/js?id=UA-7780355-10" defer="" data-nscript="beforeInteractive"></script><script src="https://insights.covermymeds.com/_next/static/chunks/webpack-494ed913da5fcfcb.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/framework-a5db9874e40342e2.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/main-49a164b0f3a8e46a.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/pages/_app-13c75eb39ee14d5c.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/2852872c-8365a197463ecf88.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/75fc9c18-5d7ef8be35b25812.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/99-c7953fb30a1e0577.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/600-f5f4b6e59ed1df20.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/964-ce4c7614b8122314.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/chunks/pages/%5Bcategory%5D/%5Btopic%5D/%5Bslug%5D-52f9a626b18dc918.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/7yVo0_otchyu3Fx5tbzU0/_buildManifest.js" defer=""></script><script src="https://insights.covermymeds.com/_next/static/7yVo0_otchyu3Fx5tbzU0/_ssgManifest.js" defer=""></script></head><body><div id="__next"><nav class="b-caption c-nav c-nav--insights"><div class="c-nav__wrap"><div class="c-nav__logo-link u-disp-flex"><a class="b-bare" href="https://covermymeds.com/main"><img class="b-bare c-nav__logo u-disp-block" width="178" height="30" src="https://images.ctfassets.net/70w6ftfzv4je/1oZePEp9g2zGMawzERET3t/d7ec9b3ededa68f326d52fd9c8799b32/logo-industry.svg" alt="CoverMyMeds Industry Home"/></a><a class="b-bare" href="../../index.html"><img class="b-bare c-nav__logo c-nav__logo--insights u-disp-block u-mar-left-10" width="84" height="30" src="https://images.ctfassets.net/70w6ftfzv4je/49UTUWqRDaswlebMdeKNeQ/bcf919b012da6a2c325199d2bcad1a67/logo-insights.svg" alt="CoverMyMeds Insights Home"/></a></div><div class="c-nav__menu"><ul class="b-bare c-nav__group"><li class="b-bare"><a class="b-bare c-nav__action" href="https://insights.covermymeds.com/healthcare-industry">Industry<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Industry"></span></a></li><li class="b-bare"><a class="b-bare c-nav__action" href="https://insights.covermymeds.com/patient-experience">Patient Experience<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Patient Experience"></span></a></li><li class="b-bare"><a class="b-bare c-nav__action" href="https://insights.covermymeds.com/healthcare-technology">Healthcare Technology<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Healthcare Technology"></span></a></li><li class="b-bare"><a class="b-bare c-nav__action" href="https://insights.covermymeds.com/medication-access-report">Reports<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Reports"></span></a></li><li class="b-bare"><a class="b-bare c-nav__action" href="https://insights.covermymeds.com/press">Press<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Press"></span></a></li><li class="b-bare"><a class="b-bare c-nav__action" href="https://experience.covermymeds.com/culture-blog">Culture<span aria-hidden="true" class="c-nav__bold-spacer" data-label="Culture"></span></a></li><li class="b-bare"><div class="c-nav__action u-mar-right-0"><a class="c-cta" href="../../subscribe/index.html"><span class="b-txt-btn c-cta__txt">Subscribe</span></a></div></li></ul></div><div class="c-nav__toggle"><button class="b-bare c-hamburger" aria-label="Toggle Navigation Menu"><span class="c-hamburger__layer"></span><span class="c-hamburger__layer"></span><span class="c-hamburger__layer"></span></button></div></div></nav><main class="itcss"><div class="o-edge "><article class="o-article-content o-article-content--full u-mar-top-80"><aside class="c-progress-bar c-progress-bar--insights c-progress-bar--hidden"><div class="o-edge u-pos-rel u-disp-flex u-align-center"><div class="c-progress-bar__logo-wrap"><a class="b-bare" href="https://www.covermymeds.com/main"><img class="b-bare c-progress-bar__logo u-disp-block" width="178" height="30" src="https://images.ctfassets.net/70w6ftfzv4je/1oZePEp9g2zGMawzERET3t/d7ec9b3ededa68f326d52fd9c8799b32/logo-industry.svg" alt="CoverMyMeds Industry Home"/></a><a class="b-bare" href="../../index.html"><img class="b-bare c-progress-bar__logo c-progress-bar__logo--insights u-disp-block u-mar-left-20" width="84" height="30" src="https://images.ctfassets.net/70w6ftfzv4je/49UTUWqRDaswlebMdeKNeQ/bcf919b012da6a2c325199d2bcad1a67/logo-insights.svg" alt="CoverMyMeds Insights Home"/></a></div><hr class="b-bare c-progress-bar__sep"/><h4 class="b-headline-4 b-headline-4--serif">Specialty Medications: Hope for Patients, Hurdle for Healthcare</h4><div class="u-mar-left-auto"><a class="c-cta" href="../../subscribe/index.html"><span class="b-txt-btn c-cta__txt">Subscribe</span><img class="c-cta__icon" src="https://images.ctfassets.net/70w6ftfzv4je/4KWzJ87hflPLKaBdDBJO9r/eac3053272e9d8dd84102dc3bf3c99b0/arrow-right.svg" alt=""/></a></div></div><progress class="c-progress-bar__indicator" min="0" value="0" max="0">Article Progress: <!-- -->NaN<!-- -->%</progress></aside><header class="o-article-content o-article-content--medium u-mar-bottom-80"><div><span class="b-txt-btn u-disp-block"><a class="b-bare o-underline-hover u-color-magenta" href="https://insights.covermymeds.com/topics/specialty-therapy">Specialty Therapy</a></span><h1 class="b-headline-2 b-headline-2--serif u-mar-top-20">Specialty Medications: Hope for Patients, Hurdle for Healthcare</h1></div><div class="o-article-content o-article-content--medium"><p class="b-body b-body--large">In part three of our History of Healthcare IT series, we explore the origins and industry response to specialty medications. Few developments in healthcare have drastically impacted stakeholders quite like the emergence and wide-spread utilization of these high-cost, high-complexity drugs.</p></div><div class="u-disp-flex u-justify-between u-align-center u-mar-vt-40"><div class="c-author u-disp-block"><div class="c-author__content"><span class="b-body b-body--serif b-body--small u-disp-block">Austin Raper, Ph.D.</span><span class="b-body b-body--serif b-body--small u-color-grey-4a u-fs-italic u-disp-block">CoverMyMeds Editorial Team</span></div></div><div class="b-body">March 22nd, 2021</div></div></header><figure class="o-article-content o-article-content--full u-mar-vt-40"><img src="https://images.ctfassets.net/70w6ftfzv4je/1Mjjrjrta45XvPzfblPoXH/7d638fe2e3959cd204d934179685fd81/Screen_Shot_2020-12-15_at_7.01.56_PM.png" class="u-disp-block u-width-100" alt="A patient receives an infusion"/><figcaption class="b-caption u-txt-right u-mar-vt-10"> </figcaption></figure><div class="o-article-content o-article-content--sidebar"><div class="b-body u-color-4a">Editor&#x27;s Note: <!-- -->This article has been updated. It was originally published in March 2019. </div><hr class="u-mar-vt-35"/><ul class="b-bare u-disp-flex u-disp-block@80"><li class="b-bare u-mar-vt-20 u-mar-right-20 u-mar-right-0@80"><a class="c-social" href="https://www.linkedin.com/shareArticle?url=https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-medications-hope-for-patients-hurdle-for-healthcare&amp;title=Specialty Medications: Hope for Patients, Hurdle for Healthcare" target="blank"><img class="c-social__button" src="https://images.ctfassets.net/70w6ftfzv4je/3l05PCFsfkuO0E69ODrskz/9a3374c46d1533075d68587179f92256/LinkedinSVG.svg" alt="LinkedIn"/></a></li><li class="b-bare u-mar-vt-20 u-mar-right-20 u-mar-right-0@80"><a class="c-social" href="https://twitter.com/share?url=https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-medications-hope-for-patients-hurdle-for-healthcare&amp;text=Specialty Medications: Hope for Patients, Hurdle for Healthcare" target="blank"><img class="c-social__button" src="https://images.ctfassets.net/2in405srp47m/5qC5FTWs5i9hldrP3Gw4RY/4ac7928183101e32fc36d2857ac65b3f/xSvg.svg" alt="Twitter"/></a></li><li class="b-bare u-mar-vt-20 u-mar-right-20 u-mar-right-0@80"><a class="c-social" href="https://www.facebook.com/sharer/sharer.php?u=https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-medications-hope-for-patients-hurdle-for-healthcare" target="blank"><img class="c-social__button" src="https://images.ctfassets.net/70w6ftfzv4je/4TWTVGhErTrzu6Pqa86Iu/3db9ce4c262a9d317b7b5a377e913615/social_fb.svg" alt="Facebook"/></a></li><li class="b-bare u-mar-vt-20"><button class="b-bare c-social"><img class="c-social__button" src="https://images.ctfassets.net/70w6ftfzv4je/5C1XXVO5g27moEkfCWLWCW/ffd9fc8936f9adabbc197186d3e30c9d/copyLink_icon.svg" alt="Copy Button"/></button></li></ul></div><div><div class="o-article-content o-article-content--drop-cap"><p class="b-body u-mar-vt-25">Beyond potential life-changing clinical benefits for patients, specialty medications have profound implications for providers, payers, pharmacies and the life sciences brands who create these therapies.</p>
<p class="b-body u-mar-vt-25">In the last in our three-part series on healthcare IT — catch up with <a class="u-color-magenta" href="https://www.covermymeds.com/main/insights/articles/the-advent-of-ehrs-and-better-patient-transparency/" title="" target="blank">part one</a> and <a class="u-color-magenta" href="https://insights.covermymeds.com/healthcare-technology/specialty-therapy/leveraging-the-human-genome-to-drive-patient-care" title="" target="blank">part two</a> — we explore the challenges associated with specialty medications and the need for electronic innovation to improve a process that’s difficult for all stakeholders.</p>
<p class="b-body u-mar-vt-25">Specialty drugs have become the fastest-growing, largest segment of the total pharmacy market in the U.S. While representing only 2.2 percent of U.S. prescription volume, these therapies accounted for 36 percent of pharmacy industry revenue in 2019 — about $161 billion.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 1" aria-expanded="false">[<!-- -->1<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="1" start="1"><a class="b-link" target="_blank" href="https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023">Medication Use and Spending in the U.S., A Review of 2018 and Outlook to 2023, IQVIA, 2019</a></span></span>,<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 2" aria-expanded="false">[<!-- -->2<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="2" start="2"><a class="b-link" target="_blank" href="https://www.drugchannels.net/2020/09/the-state-of-specialty-pharmacy-2020.html">The State of Specialty Pharmacy 2020: Market Data and Trends, Drug Channels, 2020</a></span></span></p>
<p class="b-body u-mar-vt-25">Year-over-year growth in specialty drug revenue — as well as new drug applications for specialty therapeutics at the U.S. Food &amp; Drug Administration (FDA) — underline the persistent industry trend toward specialty.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 3" aria-expanded="false">[<!-- -->3<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="3" start="3"><a class="b-link" target="_blank" href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020">New Drug Therapy Approvals 2020, U.S. Food &amp; Drug Administration, 2020</a></span></span></p>
<blockquote>
<p class="b-body u-mar-vt-25">*The number of specialty medications on the market has increased more than 1,200 percent since the mid-1990s.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 4" aria-expanded="false">[<!-- -->4<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="4" start="4"><a class="b-link" target="_blank" href="https://www.pharmacytimes.com/news/what-lies-ahead-for-pharmacists-in-2021">What Lies Ahead for Pharmacists in 2021, Pharmacy Times, 2021</a></span></span> *</p>
</blockquote></div><div class="o-article-content"><p class="b-body u-mar-vt-25">While specialty medications were once low volume — often limited to small patient populations for rare diseases like hemophilia, human immunodeficiency virus (HIV), multiple sclerosis (MS) and Gaucher’s disease<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 5" aria-expanded="false">[<!-- -->5<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="5" start="5"><a class="b-link" target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706163/pdf/bth05_2p050.pdf">The Evolution of Specialty Pharmacy, Biotechnology Healthcare, 2008</a></span></span>   — continued research into rare and complex diseases has resulted in more therapies reaching the market.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 6" aria-expanded="false">[<!-- -->6<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="6" start="6"><a class="b-link" target="_blank" href="https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases">FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021</a></span></span></p>
<p class="b-body u-mar-vt-25">Rare diseases — those affecting less than 200,00 people — collectively affect 25 to 30 million Americans, while nearly 2 million Americans are diagnosed with cancer each year.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 6" aria-expanded="false">[<!-- -->6<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="6" start="6"><a class="b-link" target="_blank" href="https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases">FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021</a></span></span>, <span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 7" aria-expanded="false">[<!-- -->7<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="7" start="7"><a class="b-link" target="_blank" href="https://www.cancer.gov/about-cancer/understanding/statistics#:~:text=Statistics%20at%20a%20Glance%3A%20The,will%20die%20from%20the%20disease">Cancer Statistics, National Cancer Institute, 2020</a></span></span></p>
<p class="b-body u-mar-vt-25">Many of these patients are presented with limited treatment options. However, by 2023, it’s projected that 65 percent of new drug launches will be specialty therapies, many indicated for rare diseases and cancer.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 8" aria-expanded="false">[<!-- -->8<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="8" start="8"><a class="b-link" target="_blank" href="https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023">The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA Institute, 2019</a></span></span></p></div><div class="o-article-content"><h2 class="b-headline-4 u-mar-top-75 u-pad-bottom-10">Features of Specialty Medications</h2>
<p class="b-body u-mar-vt-25">Specialty therapies possess a few characteristics that set them apart from traditional retail medications. Knowing these differences is important for understanding why patients can struggle with access.</p>
<ul class="b-body u-color-magenta" depth="0" node="[object Object]">
<li class="u-mar-vt-20" node="[object Object]"><div class="u-color-black"><strong>Scientific Complexity</strong>: Specialty therapies can go beyond managing symptoms to treating the underlying causes of disease. They often have targeted mechanisms of action and may be large macromolecules, termed biologics. Cell and gene therapies are also emerging as effective new treatment options for those with cancer and rare disease.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 9" aria-expanded="false">[<!-- -->9<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="9" start="9"><a class="b-link" target="_blank" href="https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/">The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018</a></span></span></div></li>
<li class="u-mar-vt-20" node="[object Object]"><div class="u-color-black"><strong>Safety Considerations</strong>: Specialty therapies can be granted priority status by the FDA, which allows for accelerated review processes. However, clinical trial enrollment for these therapies can be constrained by relatively small patient populations.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 10" aria-expanded="false">[<!-- -->10<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="10" start="10"><a class="b-link" target="_blank" href="https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review">Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, U.S. Food &amp; Drug Administration, 2018</a></span></span></div></li>
<li class="u-mar-vt-20" node="[object Object]"><div class="u-color-black"><strong>Route of Medication Administration</strong>: Many specialty therapies aren’t amenable to pill form for simple oral administration — as a result, patients may take medication via nebulization, injection or infusion.</div></li>
<li class="u-mar-vt-20" node="[object Object]"><div class="u-color-black"><strong>Cost</strong>: Consider this: In 2017, the average annual retail cost of a specialty medication was $78,781 — nearly $10,000 more than the median household income.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 11" aria-expanded="false">[<!-- -->11<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="11" start="11"><a class="b-link" target="_blank" href="https://www.aarp.org/content/dam/aarp/ppi/2019/06/trends-in-retail-prices-of-specialty-prescription-drugs-year-end-update.doi.10.26419-2Fppi.00073.001.pdf">Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update, American Association of Retired Persons, 2019</a></span></span>, <span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 12" aria-expanded="false">[<!-- -->12<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="12" start="12"><a class="b-link" target="_blank" href="https://www.census.gov/library/publications/2020/demo/p60-270.html">Income and Poverty in the United States: 2019, United States Census Bureau, 2020</a></span></span></div></li>
</ul>
<h2 class="b-headline-4 u-mar-top-75 u-pad-bottom-10">Understanding Complex Therapies</h2>
<p class="b-body u-mar-vt-25">Approved specialty medications and those in development can be complex — often far different than traditional small organic molecules. Many are classified as biopharmaceuticals — or “biologics” — and can demand novel methods for large-scale manufacturing, as well as strict storage and handling instructions. An example of this is cold-chain distribution, wherein the product is strictly temperature controlled from the time it is manufactured to immediately before administration.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 9" aria-expanded="false">[<!-- -->9<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="9" start="9"><a class="b-link" target="_blank" href="https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/">The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018</a></span></span></p>
<p class="b-body u-mar-vt-25">For some immunotherapies, like chimeric-antigen receptor T-cells (CAR-T), a cancer patient’s immune cells are removed from their body and sent to a lab for genetic-modification to specifically recognize the cancer, before being reinfused back into the patient. Such complicated science is accompanied with complicated logistics in terms of patient eligibility, provider education and therapy distribution.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 9" aria-expanded="false">[<!-- -->9<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="9" start="9"><a class="b-link" target="_blank" href="https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/">The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018</a></span></span></p>
<h2 class="b-headline-4 u-mar-top-75 u-pad-bottom-10">New Patient Insights</h2>
<p class="b-body u-mar-vt-25">The COVID-19 pandemic was especially hard on patients prescribed specialty therapies.</p>
<p class="b-body u-mar-vt-25">For the first five months of 2020, use of key autoimmune, oncology and osteoporosis drugs fell by as much as 53 percent below 2019 levels.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 13" aria-expanded="false">[<!-- -->13<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="13" start="13"><a class="b-link" target="_blank" href="https://www.iqvia.com/library/white-papers/monitoring-the-impact-of-covid-19-on-the-pharmaceutical-market">Monitoring the Impact of COVID-19 on the Pharmaceutical Market, IQVIA Institute, 2020</a></span></span> This drop can be attributed to patients distancing from medical facilities where providers administer infusion and injectable drugs.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 14" aria-expanded="false">[<!-- -->14<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="14" start="14"><a class="b-link" target="_blank" href="https://www.drugchannels.net/2020/09/specialty-pharmacy-keeps-disrupting-buy.html#:~:text=September%2023%2C%202020-,Specialty%20Pharmacy%20Keeps%20Disrupting%20Buy%2Dand%2DBill%E2%80%94and,COVID%2D19%20Will%20Accelerate%20It&amp;text=Before%20the%20pandemic%2C%20specialty%20pharmacies,of%20provider%2Dadministered%20specialty%20drugs">Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It, Drug Channels, 2020</a></span></span> Nearly half of providers CoverMyMeds surveyed reported that they changed how they approach specialty patient appointments due to COVID-19; nearly one in five providers saw a decrease in patient therapy compliance.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 15" aria-expanded="false">[<!-- -->15<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="15" start="15"><span>Provider Survey, CoverMyMeds, 2020</span></span></span></p>
<p class="b-body u-mar-vt-25">And then there’s the cost of these medications. Patients reported they’re more likely to abandon specialty therapies than any other drugs during their deductible period, when they’re responsible for paying for the bulk of their healthcare.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 16" aria-expanded="false">[<!-- -->16<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="16" start="16"><a class="b-link" target="_blank" href="https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201902.pdf">Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January–September 2018, National Center for Health Statistics, 2019</a></span></span></p>
<p class="b-body u-mar-vt-25">But while the high cost of specialty medications is a major barrier, simply accessing therapy can prove just as — if not more — difficult. Once receiving a diagnosis and prescription for a complex therapy, many patients are often left to manage their own care. Of the patients CoverMyMeds surveyed, 82 percent reported spending an hour on the phone coordinating care for specialty therapies. More than a third spent at least three hours.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 17" aria-expanded="false">[<!-- -->17<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="17" start="17"><span>Patient Survey, CoverMyMeds, 2020</span></span></span></p>
<h2 class="b-headline-4 u-mar-top-75 u-pad-bottom-10">The Evolution of Hub Services</h2>
<p class="b-body u-mar-vt-25">Specialty medications can require unique administration (nebulizer, injections, infusions), consistent patient monitoring through lab tests or regular checkups and time-intensive up-front processes, including enrollment documentation, benefit verification safety and educational components, prior authorization (PA), as well as risk evaluation and mitigation strategies (REMS).</p>
<p class="b-body u-mar-vt-25">Unfortunately, communication and coordination of efforts among the various healthcare stakeholders to fulfill these steps in a timely and efficient manner is difficult — and can lead to delays in therapy for patients. Stark differences in distribution, enrollment and reimbursement processes for specialty medications relative to traditional drugs present unique challenges to each healthcare stakeholder.</p>
<p class="b-body u-mar-vt-25">Specialty pharmacies and specialty hubs have evolved to help navigate and mitigate the challenges impeding patient access. While these services attempt to help patients and providers, the overall process is still often considered inefficient and burdensome — with manual fulfillment of steps the current standard.</p>
<p class="b-body u-mar-vt-25">Enter specialty dashboards and <a class="u-color-magenta" href="../specialty-support-5-benefits-of-an-electronic-hub/index.html" title="" target="blank">tech-enabled hub services</a>, which can electronically enroll patients during an appointment to begin therapy sooner while also reducing administrative work for provider offices. Patients can then electronically navigate affordability, benefit verification, pharmacy access and medication mode of delivery. In some cases, such inclusive patient support services have contributed to a 34 percent reduction in time to therapy.<span class="c-inline-reference "><sup><button class="b-bare o-underline-hover u-color-magenta u-fw-bold" aria-label="Footnote 18" aria-expanded="false">[<!-- -->18<!-- -->]</button></sup><span class="b-caption u-color-black u-fw-normal c-inline-reference__content" data-footnote-number="18" start="18"><span>Data on File, CoverMyMeds, 2020</span></span></span></p>
<p class="b-body u-mar-vt-25">Through continued development of <a class="u-color-magenta" href="../../../solutions/patient-support-services/index.html" title="" target="blank">electronic patient support services</a>, available at the point of prescribing for prescribers and their staff, more patients can experience end-to-end support to access specialty medications.</p>
<p class="b-body u-mar-vt-25">For more about technology’s impact on specialty medication access, <a class="u-color-magenta" href="https://insights.covermymeds.com/medication-access-report" title="" target="blank">read the 2021 Medication Access Report</a>.</p></div><div class="o-article-content u-txt-center"><a class="b-bare b-btn" href="https://insights.covermymeds.com/medication-access-report">Read more</a></div></div><div class="o-article-content u-mar-vt-80"><div class="c-author c-author--large u-disp-block"><div class="c-author__content"><span class="b-body b-body--serif u-disp-block">Austin Raper, Ph.D.</span><span class="b-body b-body--serif u-color-grey-4a u-fs-italic u-disp-block">CoverMyMeds Editorial Team</span></div></div></div><div class="o-article-content"><div class="b-caption o-expandable-source-list"><button class="b-bare u-pad-vt-20 o-expandable-source-list__btn u-disp-flex u-width-100"><div>Expand Sources</div><img class="o-expandable-source-list__arrow" src="https://images.ctfassets.net/70w6ftfzv4je/3ZNfQtyqPZ95m0ZFRrOvB5/82c57d121fa016c7c5d461cc42f51bb5/accordion-arrow.svg" alt=""/></button><ol class="b-bare o-expandable-source-list__list"><li class="b-bare u-mar-vt-10"><span>1<!-- -->.</span> <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023" class="u-color-magenta" target="_blank">Medication Use and Spending in the U.S., A Review of 2018 and Outlook to 2023, IQVIA, 2019</a></li><li class="b-bare u-mar-vt-10"><span>2<!-- -->.</span> <a href="https://www.drugchannels.net/2020/09/the-state-of-specialty-pharmacy-2020.html" class="u-color-magenta" target="_blank">The State of Specialty Pharmacy 2020: Market Data and Trends, Drug Channels, 2020</a></li><li class="b-bare u-mar-vt-10"><span>3<!-- -->.</span> <a href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020" class="u-color-magenta" target="_blank">New Drug Therapy Approvals 2020, U.S. Food &amp; Drug Administration, 2020</a></li><li class="b-bare u-mar-vt-10"><span>4<!-- -->.</span> <a href="https://www.pharmacytimes.com/news/what-lies-ahead-for-pharmacists-in-2021" class="u-color-magenta" target="_blank">What Lies Ahead for Pharmacists in 2021, Pharmacy Times, 2021</a></li><li class="b-bare u-mar-vt-10"><span>5<!-- -->.</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706163/pdf/bth05_2p050.pdf" class="u-color-magenta" target="_blank">The Evolution of Specialty Pharmacy, Biotechnology Healthcare, 2008</a></li><li class="b-bare u-mar-vt-10"><span>6<!-- -->.</span> <a href="https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases" class="u-color-magenta" target="_blank">FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021</a></li><li class="b-bare u-mar-vt-10"><span>7<!-- -->.</span> <a href="https://www.cancer.gov/about-cancer/understanding/statistics#:~:text=Statistics%20at%20a%20Glance%3A%20The,will%20die%20from%20the%20disease" class="u-color-magenta" target="_blank">Cancer Statistics, National Cancer Institute, 2020</a></li><li class="b-bare u-mar-vt-10"><span>8<!-- -->.</span> <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023" class="u-color-magenta" target="_blank">The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA Institute, 2019</a></li><li class="b-bare u-mar-vt-10"><span>9<!-- -->.</span> <a href="https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/" class="u-color-magenta" target="_blank">The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018</a></li><li class="b-bare u-mar-vt-10"><span>10<!-- -->.</span> <a href="https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review" class="u-color-magenta" target="_blank">Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, U.S. Food &amp; Drug Administration, 2018</a></li><li class="b-bare u-mar-vt-10"><span>11<!-- -->.</span> <a href="https://www.aarp.org/content/dam/aarp/ppi/2019/06/trends-in-retail-prices-of-specialty-prescription-drugs-year-end-update.doi.10.26419-2Fppi.00073.001.pdf" class="u-color-magenta" target="_blank">Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update, American Association of Retired Persons, 2019</a></li><li class="b-bare u-mar-vt-10"><span>12<!-- -->.</span> <a href="https://www.census.gov/library/publications/2020/demo/p60-270.html" class="u-color-magenta" target="_blank">Income and Poverty in the United States: 2019, United States Census Bureau, 2020</a></li><li class="b-bare u-mar-vt-10"><span>13<!-- -->.</span> <a href="https://www.iqvia.com/library/white-papers/monitoring-the-impact-of-covid-19-on-the-pharmaceutical-market" class="u-color-magenta" target="_blank">Monitoring the Impact of COVID-19 on the Pharmaceutical Market, IQVIA Institute, 2020</a></li><li class="b-bare u-mar-vt-10"><span>14<!-- -->.</span> <a href="https://www.drugchannels.net/2020/09/specialty-pharmacy-keeps-disrupting-buy.html#:~:text=September%2023%2C%202020-,Specialty%20Pharmacy%20Keeps%20Disrupting%20Buy%2Dand%2DBill%E2%80%94and,COVID%2D19%20Will%20Accelerate%20It&amp;text=Before%20the%20pandemic%2C%20specialty%20pharmacies,of%20provider%2Dadministered%20specialty%20drugs" class="u-color-magenta" target="_blank">Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It, Drug Channels, 2020</a></li><li class="b-bare u-mar-vt-10"><span>15<!-- -->.</span> <span>Provider Survey, CoverMyMeds, 2020</span></li><li class="b-bare u-mar-vt-10"><span>16<!-- -->.</span> <a href="https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201902.pdf" class="u-color-magenta" target="_blank">Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January–September 2018, National Center for Health Statistics, 2019</a></li><li class="b-bare u-mar-vt-10"><span>17<!-- -->.</span> <span>Patient Survey, CoverMyMeds, 2020</span></li><li class="b-bare u-mar-vt-10"><span>18<!-- -->.</span> <span>Data on File, CoverMyMeds, 2020</span></li></ol></div></div><div class="o-article-content o-article-content--large u-mar-vt-40"><div class="c-insights-subscribe"><div class="c-insights-subscribe__content"><h4 class="b-headline-4 u-mar-right-40@40 u-mar-bottom-20">The latest healthcare insights, floated right to your inbox.</h4><div class=""><form class="c-insights-subscribe__form"><div class="c-insights-subscribe__email"><div class="b-body c-textbox c-textbox--has-background"><label for="3JH905GyvaPGd8pexLVRb2_5ENpdH3KytP2UFVaKLUvSm_field" class=" c-textbox__label">Email address</label><input class="b-bare c-textbox__field" type="email" id="3JH905GyvaPGd8pexLVRb2_5ENpdH3KytP2UFVaKLUvSm_field" pattern="[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,4}$" name="email" required="" value=""/></div></div><div class="c-insights-subscribe__submit"><button class="c-btn u-width-100 undefined"><span class="c-btn__txt">Subscribe</span></button></div></form></div><div class="b-body u-disp-none gtm-subscribe-success">Thanks for your submission!</div><div class="b-body u-disp-none">There was an error submitting the form. Please refresh or try again later.</div></div><img class="c-insights-subscribe__phone" src="https://images.ctfassets.net/70w6ftfzv4je/ACelG83zRvus3FJWZr2CR/2c48a3e4fb653a9cfe05aafc0a2f1d3f/subscribe-phone.png" alt="iPhone showcasing News and Insights Article"/></div></div><aside class="u-mar-vt-80"><div class="u-disp-flex u-mar-bottom-80"><h2 class="b-headline-4 u-mar-right-auto">More From <!-- -->Healthcare Technology</h2><a class="b-cta" href="https://insights.covermymeds.com/healthcare-technology">View All</a></div><div class="o-story-grid o-story-grid--three-across"><div class="o-story-grid__cell"><article class="c-story c-story--stacked"><a href="https://insights.covermymeds.com/healthcare-technology/automation/four-ways-pharmacies-can-benefit-from-central-fill-as-a-service" target="_self" class="b-bare c-story__img-wrap"><img class="c-story__img" src="https://images.ctfassets.net/70w6ftfzv4je/4BS3lTxYv5a3IrvyPZRdtm/dfcc4b7ed346d72408f7d0e39d2a84e1/Four_Ways_Pharmacies_Can_Benefit_from_Central_Fill_as_a_Service_.jpeg?w=744&amp;h=444&amp;fit=fill&amp;f=face&amp;fm=jpg&amp;fl=progressive" alt="4 Ways Pharmacies Can Benefit from Central Fill as a Service"/></a><div class="c-story__text"><div class="b-bare"><a class="c-cta" href="https://insights.covermymeds.com/topics/automation"><span class="b-txt-btn c-cta__txt">Automation</span></a><a class="b-bare c-story__title" target="_self" href="https://insights.covermymeds.com/healthcare-technology/automation/four-ways-pharmacies-can-benefit-from-central-fill-as-a-service"><h3 class="b-headline-4 b-headline-4--serif u-disp-block u-mar-vt-20">4 Ways Pharmacies Can Benefit from Central Fill as a Service</h3></a></div><span class="b-body b-body--small b-body--serif u-color-grey-4a u-fs-italic">By<!-- --> <a href="https://insights.covermymeds.com/authors/melanie-christie" class="b-bare c-story__author">Melanie Christie​</a></span></div></article></div><div class="o-story-grid__cell"><article class="c-story c-story--stacked"><a href="https://insights.covermymeds.com/healthcare-technology/innovation/dtx-transport-healthcare-into-the-digital-future" target="_self" class="b-bare c-story__img-wrap"><img class="c-story__img" src="https://images.ctfassets.net/70w6ftfzv4je/5fffxdF5CxlL8z2rIprXNG/e7a86901ec9ae0bbee352504d1abd755/CMM_338823_assets_insights.jpeg?w=744&amp;h=444&amp;fit=fill&amp;f=face&amp;fm=jpg&amp;fl=progressive" alt="DTx Transport Healthcare into the Digital Future"/></a><div class="c-story__text"><div class="b-bare"><a class="c-cta" href="https://insights.covermymeds.com/topics/innovation"><span class="b-txt-btn c-cta__txt">Innovation</span></a><a class="b-bare c-story__title" target="_self" href="https://insights.covermymeds.com/healthcare-technology/innovation/dtx-transport-healthcare-into-the-digital-future"><h3 class="b-headline-4 b-headline-4--serif u-disp-block u-mar-vt-20">DTx Transport Healthcare into the Digital Future</h3></a></div><span class="b-body b-body--small b-body--serif u-color-grey-4a u-fs-italic">By<!-- --> <a href="https://insights.covermymeds.com/authors/john-beardsley" class="b-bare c-story__author">H. John Beardsley</a></span></div></article></div><div class="o-story-grid__cell"><article class="c-story c-story--stacked"><a href="https://insights.covermymeds.com/healthcare-technology/automation/6-key-advanced-pill-counting-features-pharmacies-should-consider" target="_self" class="b-bare c-story__img-wrap"><img class="c-story__img" src="https://images.ctfassets.net/70w6ftfzv4je/1NP232PDv9NxKMIIbf0wgM/63c2fa64698353b56c13b5d89e475e28/CMM_401401_assets_insights.jpeg?w=744&amp;h=444&amp;fit=fill&amp;f=face&amp;fm=jpg&amp;fl=progressive" alt="6 Key Advanced Pill-Counting Features Pharmacies Should Consider"/></a><div class="c-story__text"><div class="b-bare"><a class="c-cta" href="https://insights.covermymeds.com/topics/automation"><span class="b-txt-btn c-cta__txt">Automation</span></a><a class="b-bare c-story__title" target="_self" href="https://insights.covermymeds.com/healthcare-technology/automation/6-key-advanced-pill-counting-features-pharmacies-should-consider"><h3 class="b-headline-4 b-headline-4--serif u-disp-block u-mar-vt-20">6 Key Advanced Pill-Counting Features Pharmacies Should Consider</h3></a></div><span class="b-body b-body--small b-body--serif u-color-grey-4a u-fs-italic">By<!-- --> <a href="https://insights.covermymeds.com/authors/melanie-christie" class="b-bare c-story__author">Melanie Christie​</a></span></div></article></div></div></aside></article></div></main><footer class="b-body c-footer"><div class="c-footer__container"><div class="c-footer__link-group"><h5 class="u-fw-bold">Account</h5><ul class="b-bare"><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="https://account.covermymeds.com/">Login</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../../signup.html">Sign up</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../../request/key/index.html">Enter key</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../../user/forgot.html">Trouble logging in?</a></li></ul></div><div class="c-footer__link-group"><h5 class="u-fw-bold">Solutions</h5><ul class="b-bare"><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../solutions/patient-support-services/index.html">Patient Journey</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../solutions/medication-access.1.html">Access</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../solutions/provider/rxbc.html">Adherence</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../solutions/medication-affordability.1.html">Affordability</a></li></ul></div><div class="c-footer__link-group"><h5 class="u-fw-bold">Resources</h5><ul class="b-bare"><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../index.html">Insights</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../support/index.html">Support</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="https://insights.covermymeds.com/medication-access-report">Medication Access Report</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="https://www.covermymeds.com/main/insights/press/">Press</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../support/contact/index.html">Contact</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../support/developers/index.html">Developers</a></li></ul></div><div class="c-footer__link-group"><h5 class="u-fw-bold">Company</h5><ul class="b-bare"><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../about/index.html">About</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="https://experience.covermymeds.com/">Careers</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="https://www.covermymeds.com/main/about/leadership/">Leadership</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../about/events/index.html">Events</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../about/privacy/index.html">Privacy</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../about/privacy/responsible-disclosure-program/index.html">Responsible Disclosure Program</a></li><li class="b-bare u-mar-vt-20"><a class="c-footer__link" href="../../../partners/index.html">Our Partners</a></li></ul></div><div class="c-footer__subscribe gtm-subscribe "><h5 class="u-fw-bold">Subscribe to Insights</h5><p class="u-mar-vt-35">Get faster access to the industry news, research reports and expert opinions on key issues that matter to you.</p><form class="c-footer__form"><div class="c-footer__email"><div class="b-body c-textbox c-textbox--has-background"><label for="0SQrfavPO1spiEyLau7pO_5ENpdH3KytP2UFVaKLUvSm_field" class=" c-textbox__label">Email address</label><input class="b-bare c-textbox__field" type="email" id="0SQrfavPO1spiEyLau7pO_5ENpdH3KytP2UFVaKLUvSm_field" pattern="[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,4}$" name="email" required="" value=""/></div></div><div class="c-footer__submit"><button class="c-btn u-width-100 undefined"><span class="c-btn__txt">Subscribe</span></button></div></form></div><div class="c-footer__rule"></div><div class="b-attribution c-footer__copyright">© 2024 CoverMyMeds LLC. All Rights Reserved.</div><ul class="b-bare c-footer__social"><li class="b-bare c-footer__social-item"><a class="b-bare c-footer__icon-link" href="https://facebook.com/CoverMyMeds/" target="_blank"><img src="https://images.ctfassets.net/2in405srp47m/5chqa8TMSHhloDolfZwD3G/ad063917c3e970ca28bb2e01e1928248/social_fb.svg" class="c-footer__icon" alt="CoverMyMeds on Facebook"/></a></li><li class="b-bare c-footer__social-item"><a class="b-bare c-footer__icon-link" href="https://twitter.com/CoverMyMeds" target="_blank"><img src="https://images.ctfassets.net/2in405srp47m/5qC5FTWs5i9hldrP3Gw4RY/0fd996be97bbfac68fbf9cf9d999f420/xSvg-01.svg" class="c-footer__icon" alt="CoverMyMeds on X"/></a></li><li class="b-bare c-footer__social-item"><a class="b-bare c-footer__icon-link" href="https://linkedin.com/company/covermymeds" target="_blank"><img src="https://images.ctfassets.net/2in405srp47m/5PHW2sNqZr1spoo5aOi0bV/8cc66b8041d7657a6b772a26270d9696/social_li.svg" class="c-footer__icon" alt="CoverMyMeds on LinkedIn"/></a></li><li class="b-bare c-footer__social-item"><a class="b-bare c-footer__icon-link" href="https://instagram.com/covermymeds/" target="_blank"><img src="https://images.ctfassets.net/2in405srp47m/34nDRFOtASbqGiZWLyT82y/dcd26f73d629f867556c658a85ef79a3/social_ig.svg" class="c-footer__icon" alt="CoverMyMeds on Instagram"/></a></li><li class="b-bare c-footer__social-item"><a class="b-bare c-footer__icon-link" href="https://glassdoor.com/Overview/Working-at-CoverMyMeds-EI_IE680605.11,22.htm" target="_blank"><img src="https://images.ctfassets.net/2in405srp47m/3EvIN78HWVdY7HQyNe9C6U/5215f264b4aa45ca14cdd67b53aab609/social_gd.svg" class="c-footer__icon" alt="CoverMyMeds on Glassdoor"/></a></li></ul></div></footer></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"template":"Articles","analyticsData":{"insightsTitle":"Specialty Medications: Hope for Patients, Hurdle for Healthcare","insightsCategory":"Healthcare Technology","insightsTopic":"Specialty Therapy","insightsPublishDate":"2021-03-22T00:00:00.000Z"},"metaProps":{"title":"Specialty Medications: Hope for Patients, Hurdle for Healthcare","socialDescription":"In part three of our history of healthcare IT (HIT) series, we explore the origins and industry response to specialty medications","socialImage":"https://images.ctfassets.net/70w6ftfzv4je/1X7Qqt4nSLPN5gx6GTtIeq/94bba734d2ce5194ce571d20649bdada/CMM_119300_HealthcareIT_Pt3_hero.jpeg","pageUrl":"https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-medications-hope-for-patients-hurdle-for-healthcare"},"templateProps":{"article":{"sys":{"id":"4169ALKu52aNSnF6ROYQRb","publishedAt":"2021-03-22T18:45:58.439Z","__typename":"Sys"},"includeSectionLinks":null,"title":"Specialty Medications: Hope for Patients, Hurdle for Healthcare","slug":"specialty-medications-hope-for-patients-hurdle-for-healthcare","date":"2021-03-22T00:00:00.000Z","introduction":"In part three of our History of Healthcare IT series, we explore the origins and industry response to specialty medications. Few developments in healthcare have drastically impacted stakeholders quite like the emergence and wide-spread utilization of these high-cost, high-complexity drugs.  ","editorsNote":"This article has been updated. It was originally published in March 2019. ","category":{"title":"Healthcare Technology","slug":"healthcare-technology","__typename":"Categories"},"topic":{"title":"Specialty Therapy","slug":"specialty-therapy","__typename":"Topics"},"featureImage":{"image":{"url":"https://images.ctfassets.net/70w6ftfzv4je/1Mjjrjrta45XvPzfblPoXH/7d638fe2e3959cd204d934179685fd81/Screen_Shot_2020-12-15_at_7.01.56_PM.png","__typename":"Asset"},"altText":"A patient receives an infusion","caption":null,"photographer":null,"__typename":"ImageBlock"},"author":{"fullName":"Austin Raper, Ph.D.","jobTitle":"CoverMyMeds Editorial Team","shortBio":null,"slug":"austin-raper-phd","hasPage":false,"photo":null,"__typename":"Authors"},"bodyCollection":{"items":[{"__typename":"MarkdownBlock","sys":{"id":"72JI6w8BKkigSl5De6yB4p","__typename":"Sys"},"content":"Beyond potential life-changing clinical benefits for patients, specialty medications have profound implications for providers, payers, pharmacies and the life sciences brands who create these therapies.\n\nIn the last in our three-part series on healthcare IT — catch up with [part one](https://www.covermymeds.com/main/insights/articles/the-advent-of-ehrs-and-better-patient-transparency/) and [part two](https://insights.covermymeds.com/healthcare-technology/specialty-therapy/leveraging-the-human-genome-to-drive-patient-care) — we explore the challenges associated with specialty medications and the need for electronic innovation to improve a process that’s difficult for all stakeholders.\n\nSpecialty drugs have become the fastest-growing, largest segment of the total pharmacy market in the U.S. While representing only 2.2 percent of U.S. prescription volume, these therapies accounted for 36 percent of pharmacy industry revenue in 2019 — about $161 billion.[ref](https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023 \"Medication Use and Spending in the U.S., A Review of 2018 and Outlook to 2023, IQVIA, 2019\"),[ref](https://www.drugchannels.net/2020/09/the-state-of-specialty-pharmacy-2020.html \"The State of Specialty Pharmacy 2020: Market Data and Trends, Drug Channels, 2020\")\n\nYear-over-year growth in specialty drug revenue — as well as new drug applications for specialty therapeutics at the U.S. Food \u0026 Drug Administration (FDA) — underline the persistent industry trend toward specialty.[ref](https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020 \"New Drug Therapy Approvals 2020, U.S. Food \u0026 Drug Administration, 2020\")\n\n\u003e *The number of specialty medications on the market has increased more than 1,200 percent since the mid-1990s.[ref](https://www.pharmacytimes.com/news/what-lies-ahead-for-pharmacists-in-2021 \"What Lies Ahead for Pharmacists in 2021, Pharmacy Times, 2021\") * ","isKeyTakeaway":null},{"__typename":"MarkdownBlock","sys":{"id":"3hmwNYTLXXXkc42hShzA7T","__typename":"Sys"},"content":"While specialty medications were once low volume — often limited to small patient populations for rare diseases like hemophilia, human immunodeficiency virus (HIV), multiple sclerosis (MS) and Gaucher’s disease[ref](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706163/pdf/bth05_2p050.pdf \"The Evolution of Specialty Pharmacy, Biotechnology Healthcare, 2008\")   — continued research into rare and complex diseases has resulted in more therapies reaching the market.[ref](https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases \"FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021\")   \n\nRare diseases — those affecting less than 200,00 people — collectively affect 25 to 30 million Americans, while nearly 2 million Americans are diagnosed with cancer each year.[ref](https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases \"FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021\"), [ref](https://www.cancer.gov/about-cancer/understanding/statistics#:~:text=Statistics%20at%20a%20Glance%3A%20The,will%20die%20from%20the%20disease \"Cancer Statistics, National Cancer Institute, 2020\")\n\nMany of these patients are presented with limited treatment options. However, by 2023, it’s projected that 65 percent of new drug launches will be specialty therapies, many indicated for rare diseases and cancer.[ref](https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023 \"The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA Institute, 2019\")","isKeyTakeaway":null},{"__typename":"MarkdownBlock","sys":{"id":"5JPim5b2AniCFdwdKlXLtk","__typename":"Sys"},"content":"# Features of Specialty Medications \n\nSpecialty therapies possess a few characteristics that set them apart from traditional retail medications. Knowing these differences is important for understanding why patients can struggle with access.\n\n- __Scientific Complexity__: Specialty therapies can go beyond managing symptoms to treating the underlying causes of disease. They often have targeted mechanisms of action and may be large macromolecules, termed biologics. Cell and gene therapies are also emerging as effective new treatment options for those with cancer and rare disease.[ref](https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/  \"The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018\")\n- __Safety Considerations__: Specialty therapies can be granted priority status by the FDA, which allows for accelerated review processes. However, clinical trial enrollment for these therapies can be constrained by relatively small patient populations.[ref](https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review \"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, U.S. Food \u0026 Drug Administration, 2018\")\n- __Route of Medication Administration__: Many specialty therapies aren’t amenable to pill form for simple oral administration — as a result, patients may take medication via nebulization, injection or infusion.\n- __Cost__: Consider this: In 2017, the average annual retail cost of a specialty medication was $78,781 — nearly $10,000 more than the median household income.[ref](https://www.aarp.org/content/dam/aarp/ppi/2019/06/trends-in-retail-prices-of-specialty-prescription-drugs-year-end-update.doi.10.26419-2Fppi.00073.001.pdf \"Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update, American Association of Retired Persons, 2019\"), [ref](https://www.census.gov/library/publications/2020/demo/p60-270.html \"Income and Poverty in the United States: 2019, United States Census Bureau, 2020\") \n\n# Understanding Complex Therapies  \n\nApproved specialty medications and those in development can be complex — often far different than traditional small organic molecules. Many are classified as biopharmaceuticals — or “biologics” — and can demand novel methods for large-scale manufacturing, as well as strict storage and handling instructions. An example of this is cold-chain distribution, wherein the product is strictly temperature controlled from the time it is manufactured to immediately before administration.[ref](https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/  \"The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018\") \n\nFor some immunotherapies, like chimeric-antigen receptor T-cells (CAR-T), a cancer patient’s immune cells are removed from their body and sent to a lab for genetic-modification to specifically recognize the cancer, before being reinfused back into the patient. Such complicated science is accompanied with complicated logistics in terms of patient eligibility, provider education and therapy distribution.[ref](https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/  \"The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018\")\n\n# New Patient Insights  \n\nThe COVID-19 pandemic was especially hard on patients prescribed specialty therapies. \n\nFor the first five months of 2020, use of key autoimmune, oncology and osteoporosis drugs fell by as much as 53 percent below 2019 levels.[ref](https://www.iqvia.com/library/white-papers/monitoring-the-impact-of-covid-19-on-the-pharmaceutical-market \"Monitoring the Impact of COVID-19 on the Pharmaceutical Market, IQVIA Institute, 2020\") This drop can be attributed to patients distancing from medical facilities where providers administer infusion and injectable drugs.[ref](https://www.drugchannels.net/2020/09/specialty-pharmacy-keeps-disrupting-buy.html#:~:text=September%2023%2C%202020-,Specialty%20Pharmacy%20Keeps%20Disrupting%20Buy%2Dand%2DBill%E2%80%94and,COVID%2D19%20Will%20Accelerate%20It\u0026text=Before%20the%20pandemic%2C%20specialty%20pharmacies,of%20provider%2Dadministered%20specialty%20drugs \"Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It, Drug Channels, 2020\") Nearly half of providers CoverMyMeds surveyed reported that they changed how they approach specialty patient appointments due to COVID-19; nearly one in five providers saw a decrease in patient therapy compliance.[ref](# \"Provider Survey, CoverMyMeds, 2020\")  \n\nAnd then there’s the cost of these medications. Patients reported they’re more likely to abandon specialty therapies than any other drugs during their deductible period, when they’re responsible for paying for the bulk of their healthcare.[ref](https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201902.pdf \"Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January–September 2018, National Center for Health Statistics, 2019\") \n\nBut while the high cost of specialty medications is a major barrier, simply accessing therapy can prove just as — if not more — difficult. Once receiving a diagnosis and prescription for a complex therapy, many patients are often left to manage their own care. Of the patients CoverMyMeds surveyed, 82 percent reported spending an hour on the phone coordinating care for specialty therapies. More than a third spent at least three hours.[ref](# \"Patient Survey, CoverMyMeds, 2020\") \n\n# The Evolution of Hub Services  \n\nSpecialty medications can require unique administration (nebulizer, injections, infusions), consistent patient monitoring through lab tests or regular checkups and time-intensive up-front processes, including enrollment documentation, benefit verification safety and educational components, prior authorization (PA), as well as risk evaluation and mitigation strategies (REMS).  \n\nUnfortunately, communication and coordination of efforts among the various healthcare stakeholders to fulfill these steps in a timely and efficient manner is difficult — and can lead to delays in therapy for patients. Stark differences in distribution, enrollment and reimbursement processes for specialty medications relative to traditional drugs present unique challenges to each healthcare stakeholder. \n\nSpecialty pharmacies and specialty hubs have evolved to help navigate and mitigate the challenges impeding patient access. While these services attempt to help patients and providers, the overall process is still often considered inefficient and burdensome — with manual fulfillment of steps the current standard.  \n\nEnter specialty dashboards and [tech-enabled hub services](https://insights.covermymeds.com/healthcare-technology/specialty-therapy/specialty-support-5-benefits-of-an-electronic-hub), which can electronically enroll patients during an appointment to begin therapy sooner while also reducing administrative work for provider offices. Patients can then electronically navigate affordability, benefit verification, pharmacy access and medication mode of delivery. In some cases, such inclusive patient support services have contributed to a 34 percent reduction in time to therapy.[ref](# \"Data on File, CoverMyMeds, 2020\") \n\nThrough continued development of [electronic patient support services](https://www.covermymeds.com/main/solutions/patient-support-services/), available at the point of prescribing for prescribers and their staff, more patients can experience end-to-end support to access specialty medications. \n\nFor more about technology’s impact on specialty medication access, [read the 2021 Medication Access Report](https://insights.covermymeds.com/medication-access-report).   ","isKeyTakeaway":false},{"__typename":"CtaBlock","sys":{"id":"7bbtU82dYq2yp20fBKeVZo","__typename":"Sys"},"text":"Read more","url":"https://insights.covermymeds.com/medication-access-report"}],"__typename":"ArticlesBodyCollection"},"gate":null,"__typename":"Articles"},"relatedArticles":[{"articleTitle":"4 Ways Pharmacies Can Benefit from Central Fill as a Service","articleUrl":"https://insights.covermymeds.com/healthcare-technology/automation/four-ways-pharmacies-can-benefit-from-central-fill-as-a-service","topicTitle":"Automation","topicUrl":"/topics/automation","authorName":"Melanie Christie​","authorUrl":"/authors/melanie-christie","imageUrl":"https://images.ctfassets.net/70w6ftfzv4je/4BS3lTxYv5a3IrvyPZRdtm/dfcc4b7ed346d72408f7d0e39d2a84e1/Four_Ways_Pharmacies_Can_Benefit_from_Central_Fill_as_a_Service_.jpeg","imageAlt":"4 Ways Pharmacies Can Benefit from Central Fill as a Service","openInNewTab":false},{"articleTitle":"DTx Transport Healthcare into the Digital Future","articleUrl":"https://insights.covermymeds.com/healthcare-technology/innovation/dtx-transport-healthcare-into-the-digital-future","topicTitle":"Innovation","topicUrl":"/topics/innovation","authorName":"H. John Beardsley","authorUrl":"/authors/john-beardsley","imageUrl":"https://images.ctfassets.net/70w6ftfzv4je/5fffxdF5CxlL8z2rIprXNG/e7a86901ec9ae0bbee352504d1abd755/CMM_338823_assets_insights.jpeg","imageAlt":"DTx Transport Healthcare into the Digital Future","openInNewTab":false},{"articleTitle":"6 Key Advanced Pill-Counting Features Pharmacies Should Consider","articleUrl":"https://insights.covermymeds.com/healthcare-technology/automation/6-key-advanced-pill-counting-features-pharmacies-should-consider","topicTitle":"Automation","topicUrl":"/topics/automation","authorName":"Melanie Christie​","authorUrl":"/authors/melanie-christie","imageUrl":"https://images.ctfassets.net/70w6ftfzv4je/1NP232PDv9NxKMIIbf0wgM/63c2fa64698353b56c13b5d89e475e28/CMM_401401_assets_insights.jpeg","imageAlt":"6 Key Advanced Pill-Counting Features Pharmacies Should Consider","openInNewTab":false}],"footnoteList":[{"title":"Medication Use and Spending in the U.S., A Review of 2018 and Outlook to 2023, IQVIA, 2019","href":"https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023"},{"title":"The State of Specialty Pharmacy 2020: Market Data and Trends, Drug Channels, 2020","href":"https://www.drugchannels.net/2020/09/the-state-of-specialty-pharmacy-2020.html"},{"title":"New Drug Therapy Approvals 2020, U.S. Food \u0026 Drug Administration, 2020","href":"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020"},{"title":"What Lies Ahead for Pharmacists in 2021, Pharmacy Times, 2021","href":"https://www.pharmacytimes.com/news/what-lies-ahead-for-pharmacists-in-2021"},{"title":"The Evolution of Specialty Pharmacy, Biotechnology Healthcare, 2008","href":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706163/pdf/bth05_2p050.pdf"},{"title":"FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, 2021","href":"https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases"},{"title":"Cancer Statistics, National Cancer Institute, 2020","href":"https://www.cancer.gov/about-cancer/understanding/statistics#:~:text=Statistics%20at%20a%20Glance%3A%20The,will%20die%20from%20the%20disease"},{"title":"The Global Use of Medicine in 2019 and Outlook to 2023, IQVIA Institute, 2019","href":"https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023"},{"title":"The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs: High-Touch Services that Enhance Patient Outcomes, McKesson, 2018","href":"https://www.mckesson.com/documents/manufacturers/commercializing-gene-therapies-and-orphan-drugs/"},{"title":"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, U.S. Food \u0026 Drug Administration, 2018","href":"https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review"},{"title":"Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update, American Association of Retired Persons, 2019","href":"https://www.aarp.org/content/dam/aarp/ppi/2019/06/trends-in-retail-prices-of-specialty-prescription-drugs-year-end-update.doi.10.26419-2Fppi.00073.001.pdf"},{"title":"Income and Poverty in the United States: 2019, United States Census Bureau, 2020","href":"https://www.census.gov/library/publications/2020/demo/p60-270.html"},{"title":"Monitoring the Impact of COVID-19 on the Pharmaceutical Market, IQVIA Institute, 2020","href":"https://www.iqvia.com/library/white-papers/monitoring-the-impact-of-covid-19-on-the-pharmaceutical-market"},{"title":"Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It, Drug Channels, 2020","href":"https://www.drugchannels.net/2020/09/specialty-pharmacy-keeps-disrupting-buy.html#:~:text=September%2023%2C%202020-,Specialty%20Pharmacy%20Keeps%20Disrupting%20Buy%2Dand%2DBill%E2%80%94and,COVID%2D19%20Will%20Accelerate%20It\u0026text=Before%20the%20pandemic%2C%20specialty%20pharmacies,of%20provider%2Dadministered%20specialty%20drugs"},{"title":"Provider Survey, CoverMyMeds, 2020","href":null},{"title":"Health Insurance Coverage: Early Release of Estimates From the National Health Interview Survey, January–September 2018, National Center for Health Statistics, 2019","href":"https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201902.pdf"},{"title":"Patient Survey, CoverMyMeds, 2020","href":null},{"title":"Data on File, CoverMyMeds, 2020","href":null}]},"hideNav":false,"hideFooter":false},"__N_SSG":true},"page":"/[category]/[topic]/[slug]","query":{"category":"healthcare-technology","topic":"specialty-therapy","slug":"specialty-medications-hope-for-patients-hurdle-for-healthcare"},"buildId":"7yVo0_otchyu3Fx5tbzU0","isFallback":false,"isExperimentalCompile":false,"gsp":true,"scriptLoader":[]}</script></body></html>